Vesting

AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Tuesday, April 6, 2021
Biotechnology, Health, Genetics, Pharmaceutical, Clinical trials, Articles, Philosophy, Branches of philosophy, Inheritance, Labour law, Property law, Vesting, Gene therapy, Forward-looking statement, Therapy, Plato

The grants were made in accordance with Nasdaq Listing Rule 5635(c)(4).

Key Points: 
  • The grants were made in accordance with Nasdaq Listing Rule 5635(c)(4).
  • Vesting of the option awards is subject to continued service with AVROBIO by the employee through the applicable vesting dates.
  • AVROBIO is powered by our industry leading plato gene therapy platform, our foundation designed to deliver gene therapy worldwide.
  • AVROBIO explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.

Recro Reports Inducement Grants for New Staff

Retrieved on: 
Tuesday, April 6, 2021
Law, Private law, Inheritance, Labour law, Property law, Vesting, Executive compensation, Contract, NASDAQ, Employment, Articles

In connection with the hiring of these personnel, the compensation committee of Recros board of directors approved inducement stock option grants to purchase an aggregate of 98,843 shares of Recros common stock.

Key Points: 
  • In connection with the hiring of these personnel, the compensation committee of Recros board of directors approved inducement stock option grants to purchase an aggregate of 98,843 shares of Recros common stock.
  • The equity awards were granted pursuant to the NASDAQ inducement grant exception as a component of each individuals employment compensation and were granted as an inducement material to his or her acceptance of employment with Recro in accordance with NASDAQ Listing Rule 5635(c)(4).
  • The equity awards are subject to each individuals continued service with Recro through the applicable vesting dates.
  • Recro (NASD: REPH ) is a contract development and manufacturing organization (CDMO) with capabilities from early feasibility to commercial manufacturing.

Chinook Therapeutics Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Thursday, April 1, 2021
Corporate finance, Financial economics, Finance, Stock market, Inheritance, Labour law, Property law, Vesting, Law, Stock

The stock options vest over four years, with 25% vesting on each employees start date and 1/36th of the shares vesting monthly thereafter, subject to each employees continued employment on each such date.

Key Points: 
  • The stock options vest over four years, with 25% vesting on each employees start date and 1/36th of the shares vesting monthly thereafter, subject to each employees continued employment on each such date.
  • The stock options have a 10-year term and are subject to the terms and conditions of the stock option agreement.
  • The Company granted the stock options as a material inducement to these employees for entering into employment with Chinook Therapeutics, Inc. in accordance with Nasdaq listing Rule 5635(c)(4).
  • Chinook Therapeutics, Inc. is a clinical-stage biotechnology company developing precision medicines for kidney diseases.

Cidara Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Thursday, April 1, 2021
Law, Private law, Contract law, Inheritance, Labour law, Property law, Vesting, Inducement rule, Articles, Good faith

The awards are subject to the award holders continuous service through each vesting date and to the terms and conditions of the companys 2020 Inducement Incentive Plan and its standard forms of grant agreements thereunder.

Key Points: 
  • The awards are subject to the award holders continuous service through each vesting date and to the terms and conditions of the companys 2020 Inducement Incentive Plan and its standard forms of grant agreements thereunder.
  • Theforegoingequity awardswere granted as inducements material to the employees entering into employmentwith Cidara,in accordance withNasdaq Listing Rule 5635(c)(4).The Cidara Therapeutics, Inc. 2020InducementIncentivePlan is used exclusively for the grant of equity awards to individuals who were not previously employees ofCidara,or following a bona fide period of non-employment, as an inducement material to such individuals entering into employment withCidara, pursuant toNasdaq Listing Rule 5635(c)(4).
  • Cidara is developing long-acting therapeuticsdesignedtotransformthe standard of care for patients facing serious fungal or viral infections.
  • Cidara is headquartered in San Diego, California.

Baudax Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Thursday, April 1, 2021
Private law, Law, Inheritance, Labour law, Property law, Vesting, Contract law, NASDAQ, Option, Articles

The equity award was granted pursuant to the Nasdaq Rule 5635(c)(4) inducement grant exception as a component of the individuals employment compensation and was granted as an inducement material to his acceptance of employment with Baudax Bio.

Key Points: 
  • The equity award was granted pursuant to the Nasdaq Rule 5635(c)(4) inducement grant exception as a component of the individuals employment compensation and was granted as an inducement material to his acceptance of employment with Baudax Bio.
  • The options have an exercise price equal to $1.29 per share, the closing price of Baudax Bios common stock as reported by Nasdaq on March 31, 2021.
  • The equity awards are subject to the employees continued service with Baudax Bio through the applicable vesting dates.
  • Such forward-looking statements reflect Baudax Bios expectations about its future performance and opportunities that involve substantial risks and uncertainties.

Eve Sleep plc: Director/PDMR Shareholding

Retrieved on: 
Friday, March 26, 2021
Articles, Geology, Earth sciences, Inheritance, Labour law, Property law, Vesting, Volatiles, Option

eve, adirect to consumer sleep wellness brandoperating in theUK, Ireland and France, today announces that Cheryl Calverley, Chief Executive Officer of the Company and Tim Parfitt, Chief Financial Officer of the Company have been granted options to subscribe for an aggregate of 600,000 ordinary shares of 0.1p each in the Company ("Ordinary Shares" and the "Options").

Key Points: 
  • eve, adirect to consumer sleep wellness brandoperating in theUK, Ireland and France, today announces that Cheryl Calverley, Chief Executive Officer of the Company and Tim Parfitt, Chief Financial Officer of the Company have been granted options to subscribe for an aggregate of 600,000 ordinary shares of 0.1p each in the Company ("Ordinary Shares" and the "Options").
  • The Options vest from their start date on a straight-line basis over a three-year vesting period in monthly increments.
  • Following the grant of the Options, Cheryl Calverley and her connected persons have an interest in 368,004 Ordinary Shares and 4,712,500 Options and Tim Parfitt and his connected persons have an interest in 627,048 Ordinary Shares and 2,200,000 Options.
  • The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.

Trailbreaker Resources Announces the Granting of Stock Options

Retrieved on: 
Wednesday, March 24, 2021
Options, Employee compensation in the United States, Employee stock option, Labour law, Property law, Vesting, Incentive stock option, Toronto Stock Exchange, Law, Private law, Articles

VANCOUVER, British Columbia, March 24, 2021 (GLOBE NEWSWIRE) -- Trailbreaker Resources Ltd. (TBK.V) (Trailbreaker or the Company) is pleased to announce the granting of stock options to Mr. Frank Wheatley.

Key Points: 
  • VANCOUVER, British Columbia, March 24, 2021 (GLOBE NEWSWIRE) -- Trailbreaker Resources Ltd. (TBK.V) (Trailbreaker or the Company) is pleased to announce the granting of stock options to Mr. Frank Wheatley.
  • Mr. Wheatley was elected by the shareholders as Independent Director at the 2020 Annual General Meeting (AGM) and appointed by the Board as Chairman of the Audit Committee for Trailbreaker Resources Ltd.
  • The company has granted Mr. Wheatley 150,000 incentive stock options exercisable at a price of$0.30per share for a term of five years expiringMarch 24th, 2026, vesting immediately.
  • The options are granted in accordance with the Company's stock option plan and as set forth by TSX Venture Exchange ("TSX-V") policy and are subject to all regulatory approvals.

CGX Energy Completes Grant of Previously Announced Stock Options

Retrieved on: 
Tuesday, March 23, 2021
Options, Employee stock option, Private law, Employee compensation in the United States, Law, Incentive stock option, Taxation in the United States, Vesting, Articles

Toronto, Ontario--(Newsfile Corp. - March 23, 2021) - CGX Energy Inc. (TSXV: OYL) ("CGX Energy" or the "Company"), announces that it has completed the grant of incentive stock options ("Options") previously announced on February 8, 2021 related to the appointment of Professor Mark D. Zoback as a Director of the Company and Ms. Jennifer Budlong as Exploration Manager.

Key Points: 
  • Toronto, Ontario--(Newsfile Corp. - March 23, 2021) - CGX Energy Inc. (TSXV: OYL) ("CGX Energy" or the "Company"), announces that it has completed the grant of incentive stock options ("Options") previously announced on February 8, 2021 related to the appointment of Professor Mark D. Zoback as a Director of the Company and Ms. Jennifer Budlong as Exploration Manager.
  • The stock options were granted on March 23, 2021 pursuant to the Company's stock option plan and are exercisable at a price of $0.82 per share, set to expire on March 23, 2026.
  • These Options vest as follows: (a) 1/3 of the Options granted immediately; (b) 1/3 of the Options granted on the six month anniversary of the Option grant; and (c) 1/3 of the Options granted, being the remaining amount, on the first anniversary of the Option grant, subject to a vesting acceleration clause under certain events.
  • CGX Energy is a Canadian-based oil and gas exploration company focused on the exploration of oil in the Guyana-Suriname Basin.

Sesen Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Monday, March 22, 2021
Biotechnology, FDA, Health, General Health, Pharmaceutical, Oncology, Other Science, Research, Genetics, Science, Clinical trials, Inheritance, Labour law, Property law, Vesting, NASDAQ, Law, Private law, Finance, Vicineum™, Sesen Bio

Under the grants of non-statutory stock options, up to 160,000 shares of Sesen Bio common stock are purchasable upon vesting of the stock options within the ten-year term.

Key Points: 
  • Under the grants of non-statutory stock options, up to 160,000 shares of Sesen Bio common stock are purchasable upon vesting of the stock options within the ten-year term.
  • Each of the options was granted as a material inducement to employment in accordance with Nasdaq Listing Rule 5635(c)(4).
  • Sesen Bio, Inc. is a late-stage clinical company advancing targeted fusion protein therapeutics for the treatment of patients with cancer.
  • Sesen Bio continues to monitor the rapidly evolving environment regarding the potential impact of the COVID-19 pandemic on our Company.

Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Friday, March 19, 2021
Health, Pharmaceutical, Corporate finance, Stock market, Finance, Financial economics, Money, Employee stock ownership, Fundamental analysis, Restricted stock, Vesting, Executive compensation, Stock, Option

Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that the Compensation Committee of its Board of Directors granted inducement stock options, inducement performance restricted stock units ("PRSUs"), and inducement restricted stock units ("RSUs") to new employees.

Key Points: 
  • Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that the Compensation Committee of its Board of Directors granted inducement stock options, inducement performance restricted stock units ("PRSUs"), and inducement restricted stock units ("RSUs") to new employees.
  • The inducement stock options, PRSUs, and RSUs each have a grant date and vesting commencement date (if applicable) of March 15, 2021, and were granted as inducements material to the new employees entering employment with Arena in accordance with Nasdaq Listing Rule 5635(c)(4).
  • ARENA Pharmaceuticals is a team with a singular purpose deliver our important medicines to patients.
  • Arena disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.